Trial Profile
Phase I Clinical Study of Combination Therapy with Eribulin and Gemcitabine in Patients with Progressive Recurring Breast Cancer (JBCRG-18Gem)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Gemcitabine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms JBCRG-18Gem
- 22 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by University Hospital Medical Information Network - Japan.
- 25 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 31 Dec 2013 Planned End Date changed from 30 Nov 2013 to 30 Nov 2014 as reported by University Hospital Medical Information Network - Japan.